VJHemOnc is committed to improving our service to you

EBMT 2020 | The management & optimization of CAR T-cell therapy in myeloma

VJHemOnc is committed to improving our service to you

Michel Delforge

CAR T-cell therapy offers many opportunities, but also challenges. Michel Delforge, MD, PhD, University of Leuven, Leuven, Belgium, discusses the management and optimization of CAR T-cell therapy in multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter